FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2111489716> ?p ?o ?g. }

• W2111489716 endingPage "772" @default.
• W2111489716 startingPage "757" @default.
• W2111489716 abstract "This study aimed at evaluating the collision-induced dissociation tandem mass spectrometric (CID-MS/MS) fragmentation patterns of novel β-cyclodextrin-substituted- and bis-pyridinium gemini surfactants currently being explored as nanomaterial drug delivery agents. In the β-cyclodextrin-substituted gemini surfactants, a β-cyclodextrin ring is grafted onto an N,N-bis(dimethylalkyl)-α,ω-aminoalkane-diammonium moiety using variable succinyl linkers. In contrast, the bis-pyridinium gemini surfactants are based on a 1,1'-(1,1'-(ethane-1,2-diylbis(sulfanediyl))bis(alkane-2,1-diyl))dipyridinium template, defined by two symmetrical N-alkylpyridinium parts connected through a fixed ethane dithiol spacer.Detection of the precursor ion [M](2+) species of the synthesized compounds and the determination of mass accuracies were conducted using a QqTOF-MS instrument. A multi-stage tandem MS analysis of the detected [M](2+) species was conducted using the QqQ-LIT-MS instrument. Both instruments were equipped with an electrospray ionization (ESI) source.Abundant precursor ion [M](2+) species were detected for all compounds at sub-1 ppm mass accuracies. The β-cyclodextrin-substituted compounds, fragmented via two main pathways: Pathway 1: the loss of one head-tail region produces a [M-(N(Me)2-R)](2+) ion, from which sugar moieties (Glc) are sequentially cleaved; Pathway 2: both head-tail regions are lost to give [M-2(N(Me)2-R)](+), followed by consecutive loss of Glc units. Alternatively, the cleavage of the Glc units could also have occurred simultaneously. Nevertheless, the fragmentation evolved around the quaternary ammonium cations, with characteristic cleavage of Glc moieties. For the bis-pyridinium gemini compounds, they either lost neutral pyridine(s) to give doubly charged ions (Pathway A) or formed complementary pyridinium alongside other singly charged ions (Pathway B). Similar to β-cyclodextrin-substituted compounds, the fragmentation was centered on the pyridinium functional groups.The MS(n) analyses of these novel gemini surfactants, reported here for the first time, revealed diagnostic ions for each compound, with a universal fragmentation pattern for each compound series. The diagnostic ions will be employed within liquid chromatography (LC)/MS/MS methods for screening, identification, and quantification of these compounds within biological samples." @default.
• W2111489716 created "2016-06-24" @default.
• W2111489716 creator A5005526651 @default.
• W2111489716 creator A5034470962 @default.
• W2111489716 creator A5042906285 @default.
• W2111489716 creator A5053348228 @default.
• W2111489716 date "2014-02-27" @default.
• W2111489716 modified "2023-10-06" @default.
• W2111489716 title "Multi-stage tandem mass spectrometric analysis of novel β-cyclodextrin-substituted and novel bis-pyridinium gemini surfactants designed as nanomedical drug delivery agents" @default.
• W2111489716 cites W1760140670 @default.
• W2111489716 cites W1982747064 @default.
• W2111489716 cites W1996601547 @default.
• W2111489716 cites W1998878299 @default.
• W2111489716 cites W2004228506 @default.
• W2111489716 cites W2004434034 @default.
• W2111489716 cites W2010050885 @default.
• W2111489716 cites W2023907922 @default.
• W2111489716 cites W2024597240 @default.
• W2111489716 cites W2040275047 @default.
• W2111489716 cites W2040631980 @default.
• W2111489716 cites W2044407315 @default.
• W2111489716 cites W2065805558 @default.
• W2111489716 cites W2069799255 @default.
• W2111489716 cites W2074857690 @default.
• W2111489716 cites W2077297055 @default.
• W2111489716 cites W2078464167 @default.
• W2111489716 cites W2081337065 @default.
• W2111489716 cites W2082347323 @default.
• W2111489716 cites W2083804102 @default.
• W2111489716 cites W2088610467 @default.
• W2111489716 cites W2098468315 @default.
• W2111489716 cites W2101551406 @default.
• W2111489716 cites W2109474157 @default.
• W2111489716 cites W2147013877 @default.
• W2111489716 cites W2164253249 @default.
• W2111489716 cites W2331051980 @default.
• W2111489716 cites W2506619772 @default.
• W2111489716 cites W4231635416 @default.
• W2111489716 doi "https://doi.org/10.1002/rcm.6827" @default.
• W2111489716 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24573807" @default.
• W2111489716 hasPublicationYear "2014" @default.
• W2111489716 type Work @default.
• W2111489716 sameAs 2111489716 @default.
• W2111489716 citedByCount "19" @default.
• W2111489716 countsByYear W21114897162014 @default.
• W2111489716 countsByYear W21114897162015 @default.
• W2111489716 countsByYear W21114897162016 @default.
• W2111489716 countsByYear W21114897162017 @default.
• W2111489716 countsByYear W21114897162018 @default.
• W2111489716 countsByYear W21114897162019 @default.
• W2111489716 countsByYear W21114897162020 @default.
• W2111489716 countsByYear W21114897162021 @default.
• W2111489716 countsByYear W21114897162023 @default.
• W2111489716 crossrefType "journal-article" @default.
• W2111489716 hasAuthorship W2111489716A5005526651 @default.
• W2111489716 hasAuthorship W2111489716A5034470962 @default.
• W2111489716 hasAuthorship W2111489716A5042906285 @default.
• W2111489716 hasAuthorship W2111489716A5053348228 @default.
• W2111489716 hasConcept C102931765 @default.
• W2111489716 hasConcept C111919701 @default.
• W2111489716 hasConcept C155647269 @default.
• W2111489716 hasConcept C162356407 @default.
• W2111489716 hasConcept C176107965 @default.
• W2111489716 hasConcept C178790620 @default.
• W2111489716 hasConcept C185592680 @default.
• W2111489716 hasConcept C191015642 @default.
• W2111489716 hasConcept C194451485 @default.
• W2111489716 hasConcept C21951064 @default.
• W2111489716 hasConcept C2776568683 @default.
• W2111489716 hasConcept C2777221202 @default.
• W2111489716 hasConcept C2779433975 @default.
• W2111489716 hasConcept C31827203 @default.
• W2111489716 hasConcept C40684141 @default.
• W2111489716 hasConcept C41008148 @default.
• W2111489716 hasConcept C43617362 @default.
• W2111489716 hasConcept C71240020 @default.
• W2111489716 hasConceptScore W2111489716C102931765 @default.
• W2111489716 hasConceptScore W2111489716C111919701 @default.
• W2111489716 hasConceptScore W2111489716C155647269 @default.
• W2111489716 hasConceptScore W2111489716C162356407 @default.
• W2111489716 hasConceptScore W2111489716C176107965 @default.
• W2111489716 hasConceptScore W2111489716C178790620 @default.
• W2111489716 hasConceptScore W2111489716C185592680 @default.
• W2111489716 hasConceptScore W2111489716C191015642 @default.
• W2111489716 hasConceptScore W2111489716C194451485 @default.
• W2111489716 hasConceptScore W2111489716C21951064 @default.
• W2111489716 hasConceptScore W2111489716C2776568683 @default.
• W2111489716 hasConceptScore W2111489716C2777221202 @default.
• W2111489716 hasConceptScore W2111489716C2779433975 @default.
• W2111489716 hasConceptScore W2111489716C31827203 @default.
• W2111489716 hasConceptScore W2111489716C40684141 @default.
• W2111489716 hasConceptScore W2111489716C41008148 @default.
• W2111489716 hasConceptScore W2111489716C43617362 @default.
• W2111489716 hasConceptScore W2111489716C71240020 @default.
• W2111489716 hasFunder F4320334593 @default.
• W2111489716 hasIssue "7" @default.
• W2111489716 hasLocation W21114897161 @default.
• W2111489716 hasLocation W21114897162 @default.

• next